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ABSTRACT
This article focuses on the necessary psychometric proper-
ties of a patient-reported outcomes (PROs) measure. Topics
include the importance of reliability and validity, psycho-
metric approaches used to provide reliability and validity
estimates, the kinds of evidence needed to indicate that a
PRO has a sufﬁcient level of reliability and validity, con-
texts that may affect psychometric properties, methods
available to evaluate PRO instruments when the context
varies, and types of reliability and validity testing that are
appropriate during different phases of clinical trials.
Points discussed include the perspective that the psycho-
metric properties of reliability and validity are on a con-
tinuum in which the more evidence one has, the greater
conﬁdence there is in the value of the PRO data. Construct
validity is the type of validity most frequently used with PRO
instruments as few “gold standards” exist to allow the use of
criterion validity and content validity by itself only provides
beginning evidence of validity.
Several guidelines are recommended for establishing sufﬁ-
cient evidence of reliability and validity. For clinical trials, a
minimum reliability threshold of 0.70 is recommended.
Sample sizes for testing should include at least 200 cases and
results should be replicated in at least one additional sample.
At least one full report on the development of the instrument
and one on the use of the instrument are deemed necessary to
evaluate the PRO psychometric properties. Psychometric
testing ideally occurs before the initiation of Phase III trials.
When testing does not occur prior to a Phase III trial, con-
siderable risk is posed in relation to the ability to substantiate
the use of the PRO data. Various qualitative (e.g., focus
groups, behavioral coding, cognitive interviews) and quanti-
tative approaches (e.g., differential item functioning testing)
are useful in evaluating the reliability and validity of PRO
instruments.
Keywords: patient-reported outcomes, psychometric,
validation.
Introduction
Evaluation of health-care interventions in clinical trials
has traditionally focused on efﬁcacy and safety.
Patient-reported outcomes (PROs), outcomes directly
reported by the patient, are increasingly being consid-
ered and used as part of these evaluations. PROs
include symptoms and other aspects of health-related
quality of life such as physical or social function, treat-
ment adherence, and satisfaction with treatment [1,2].
As with more traditional efﬁcacy and safety end points,
reliable and valid instruments are needed to measure
PROs.
PROs are distinct from traditional clinical efﬁcacy
measures (e.g., survival in cancer, smoking cessation
rates, laboratory test results). PROs directly reﬂect the
impact of disease and its treatment from the patient’s
perspective and can measure the tradeoff between efﬁ-
cacy of the treatment and what the patient is willing
to tolerate [3]. PROs are especially signiﬁcant when
symptoms, functioning, and well-being are important
outcomes or areas of concern. They are particularly
informative when interventions reveal otherwise
similar efﬁcacy and safety using traditional clinical
measures or when an intervention provides only a
small clinical beneﬁt. Because PROs reﬂect the
patient’s perspective, they have the potential to facili-
tate patient involvement in treatment decision-making
and provide guidance for health-care decisions.
The ability of a PRO measure to improve decision-
making in clinical research relies on the psychometric
strength of the instrument to capture the burden of
disease or treatment. Reliability and validity are essen-
tial psychometric properties for any measure [4]. Evi-
dence for an instrument’s reliability and validity falls
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along a continuum from no evaluation to full evalua-
tion for the study population. Thus, both reliability
and validity are more accurately described as “con-
tinuous” rather than “dichotomous” psychometric
indices. For this reason, claiming that an instrument
is completely “reliable” or “valid” is inaccurate.
Similarly, saying an instrument has been “validated”
conveys no information other than to say its perfor-
mance or psychometric properties have been evalu-
ated. The more evidence that the instrument is reliably
measuring the speciﬁc PRO it is supposed to be mea-
suring the more conﬁdence one has in it.
Reliability and validity are separate psychometric
properties. An instrument that is not reliable (internal
consistency, test–retest) by deﬁnition cannot be valid.
Measures can be highly reliable but not measure what
they are purported to measure. For example, a self-
report of year in school (e.g., third, fourth, ﬁfth grade)
by elementary students may be very reliable but this
would not be a valid measure of grade school success
because of the low dropout rate at that age and large
variation in performance within the same grade level.
Thus, reliability is necessary but not sufﬁcient in deter-
mining validity.
This article focuses on the necessary psychometric
properties to support use of PROs in health-care inter-
vention evaluations in clinical trials. Speciﬁcally
addressed are: 1) the importance of reliability and
validity; 2) the psychometric approaches used to
provide reliability and validity estimates; 3) the evi-
dence needed to indicate that a PRO has a sufﬁcient
level of reliability and validity; 4) contexts that may
affect psychometric properties; 5) methods available to
establish the reliability and validity of PRO instru-
ments when the context varies; and 6) types of reliabil-
ity and validity testing that are appropriate during
different phases of clinical trials. The discussions are
intended to address the need to evaluate instrument
properties as proposed by the Food and Drug Admin-
istration (FDA) in its guidance on PROs for labeling
claims (see Fig. 1) [5].
Reliability andValidity Performance
Recommendations
Reliability
The ﬁrst attribute evaluated and reported typically is
reliability, the extent to which a measure yields the
same number or score each time it is administered
when the construct being measured has not changed.
Internal consistency reliability, the primary method of
estimating reliability for multi-item scales, provides
information about the associations among different
items in the scale. Internal consistency is typically
indexed by Cronbach’s coefﬁcient alpha, which is esti-
mated using a two-way ﬁxed-effect analysis of variance
(ANOVA) that partitions the “signal” (i.e., between
person variance) from the “noise” (i.e., interaction
between people and responses to different items).
Alpha can also be expressed using the formula:
Alpha K R K Rii ii= ∗( ) + −( )∗( )1 1
This alternative expression illustrates how reliability
increases with the number of items (K) in a scale and
the strength of the correlations among items as repre-
sented by the intraclass correlation (Rii). Rii represents
the estimated reliability for a single item. Applying
the formula, a scale with an intraclass correlation of
0.30 and ﬁve items will have an estimated reliability of
0.68. Thus, a PRO measurement with multi-item
scales yields more precise measurement of PRO con-
structs than a single-item measure.
i.  Identify Concepts & Develop Conceptual Framework
Identify concepts and domains that are important to patients.
Identify intended population and research application.
Hypothesize expected relationships among concepts.
ii. Create Instrument
Generate items.
Choose administration method,
recall period, and response scales.
Draft instructions.
Format instruments.
Draft procedures for scoring and
administration. Pilot test draft 
instrument. Refine instrument and 
procedures.
iii. Assess Measurement Properties
Assess score reliability, validity, and ability to detect change.
Evaluate administrative and response burden.  Add, delete, or revise items.
Identify meaningful differences in scores.  Finalize instrument formats,
scoring, procedures, and training materials.
iv.  Modify Instrument
Change concepts measured,
Populations studied, 
Research application,
instrumentation,
or methods of administration.
PRO
Development
Figure 1 PRO development from PRO draft
guidance [5]. PRO, patient-reported outcome.
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Beyond statistical considerations, multi-item scales
better capture multiple attributes that underlie PRO
domains like pain, fatigue, or nausea. Although the
trade-off with longer scales is increased response
burden, the improved precision and validity added
with well designed multi-item scales (over single-item
measures) enhances conﬁdence in any decision regard-
ing clinical effectiveness. Coefﬁcient alpha would not
be appropriate for single item scales or to compute
coefﬁcient alpha for a set of items that measure differ-
ent constructs (e.g., a variety of potentially unrelated
symptoms).
Picking the optimal time interval for test–retest reli-
ability may be difﬁcult. Repeat administration timing
should not be so soon that responses at the second
assessment are simply memories of the ﬁrst assessment;
yet it should also not be so long that true change in
the construct has occurred during the time interval
between the initial and subsequent assessment.
Reliability coefﬁcients range in theory between 0
and 1, with 0.70 the standard threshold for adequate
reliability for use of measures for group comparisons.
For individual applications, a more stringent minimum
threshold of 0.90 reliability has been suggested [4,6].
The higher standard is needed because the error
around an individual’s score is larger than the error
around a group mean score. For example, even with a
reliability of 0.91, the individual’s standard error of
measurement (SEM) (standard deviation [SD]  square
root of 1—reliability coefﬁcient) is equal to 0.30  SD.
If the SD of a measure is 10 as it is with the SF-36v2™
scales, then the width of the 95% conﬁdence interval
(CI) around an individual’s score is 12 points (greater
than a SD) as it extends from 6 points below to 6
points above the estimated true score. Using the same
instrument in a group, a sample size of 25 people
would yield a width of the 95% CI around the group
mean of 2.4 points (approximately one-quarter of a
SD). Clinical trials are group applications and because
the error of measurement of group means is driven
primarily by sample size, a 0.70 reliability threshold is
appropriate.
Reliability and SEM are inversely related. This asso-
ciation has important implications for the sample size
needed to detect group differences (longitudinally or
cross-sectionally) in PRO measures. For example,
adjusting for the SEM, the required sample size per
group to detect one-third of a SD difference between
baseline and follow-up is 297 versus 227 per group if
the reliability is 0.69 versus 0.84, respectively [7,8].
Thus, increased reliability in the PRO measure reduces
the sample size needed in the example by 70 people.
The limitation of the traditional measures of reli-
ability is that they assume that the reliability of a scale
is ﬁxed for all score levels. For example, a pain instru-
ment with a reliability of 0.82 would be considered
acceptable for measuring a group’s average state of
pain no matter if the group experiences mild, average,
or severe levels of pain.
In contrast, item response theory (IRT) provides
an assessment of reliability of item and scale infor-
mation curves. The IRT information curve indicates
the precision of an item or scale for measuring dif-
ferent levels along its underlying trait continuum (see
Fig. 2). Items are most useful when they are appro-
priate or matched to the individual completing it. For
example, asking a person who is generally happy and
content with life about thoughts of suicide in the last
week is not likely to be informative for measuring his
or her emotional distress level. Items are most infor-
mative when the answer that someone will give is less
certain (e.g., just as likely to say “yes” as “no” to a
dichotomous question). Because of the emphasis on
assessing dysfunction, information curves for PRO
measures often reﬂect higher precision for measuring
low function than for measuring high function.
Item Discrimination across Scales: Approach to Enhance
Reliability and Validity
Internal consistency reliability provides information
about the associations among different items in the
scale. Equally important is to evaluate the extent to
which items in one scale distinctively represent that
construct rather than any other related constructs. One
approach to evaluating the distinctiveness of different
measures is multi-trait scaling analysis [9]. This
method examines correlations between items and
scales, which indicates if the item uniquely represents
the hypothesized scale. Conﬁrmatory factor analysis
provides a parallel and more sophisticated approach to
evaluating item discrimination across scales [10].
Validity
A PRO measure must distinctly deﬁne one construct
and not overlap with other putatively distinct con-
cepts. Validity refers to the extent to which an instru-
ment measures what it was intended to measure and
not something else. Generally, a strong correlation
should be demonstrated with measures addressing
similar constructs and a weak correlation with mea-
sures addressing disparate constructs. There are three
main subtypes of validity: content, criterion, and
construct.
Content validity. This is the extent to which the PRO
instrument measures the appropriate content and rep-
resents the variety of attributes that make up the mea-
sured construct. Another way of expressing content
validity is the adequacy of sampling of the material in
the measure, which is best ensured by a plan for
content and item construction before the measure
is developed. Focus groups and other qualitative
methods (e.g., cognitive interviews) are sources for
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appropriate content. A group of experts can examine
items and can either endorse the content validity or
identify any important gaps in content. Face validity
assesses the content of a scale in terms of the extent to
which it is perceived to be measuring what it is sup-
posed to measure by patients and experts.
Criterion validity. This refers to the extent to which
the measure agrees with an external standard measure.
An example would be the development of an observa-
tional measure of how well an individual is breathing
and comparing it to of a pulse oximeter reading that
measures oxygen saturation.
Because PRO measures typically have no standard,
criterion validity is usually not applicable. For situa-
tions where it is appropriate, evaluation of criterion
validity would involve determining the extent to which
the newmeasure is consistent or captures the essence of
the standard measure. For example, one might employ
contingency table analyses of sensitivity and speciﬁcity
or area under the curve analyses to assess the level of
agreement of the new measure with the standard [11].
Construct validity. This is the extent to which the
measure “behaves” in a way consistent with theoreti-
cal hypotheses; it represents how well scores on the
instrument are indicative of the theoretical PRO con-
struct. Construct validity evaluation includes the
degree to which a measure correlates with other mea-
sures to which it is similar and does not correlate with
Item Response Theory (IRT) Modeling
Item Information Curve
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Figure 2 Item Response Theory (IRT) infor-
mation curves. MMPI, Minnesota Multiphasic
Personality Inventory.
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(diverges from) measures that are dissimilar. A surplus
of terminology exists in the literature that falls into the
general class of construct validity. For example, the
multi-trait-multi-method of validity assessment refers
to convergent and discriminant validity as aspects of
construct validity.
Responsiveness measures an instrument’s ability to
capture change [12]. Responsiveness is often over-
looked and yet is vital when using repeated measures
over time when the concept is known to have changed.
Construct validity is typically examined using
bivariate correlations, factor analysis, and multivariate
regression models. For example, one could hypothesize
that a breast cancer patient’s self-esteem was positively
associated with breast-conserving surgery. One could
regress self-esteem on type of surgery and background
variables such as age, marital status, and educational
level. A statistically signiﬁcant ﬁnding for type of
surgery would support the hypothesis and construct
validity of the measure of self-esteem.
Level of Psychometric Evidence to Support
Use of PROs in Clinical Trials
Both qualitative and quantitative information are
important in evaluating the level of evidence to
support reliability and validity. Multiple pieces of
evidence should support use of a PRO measure (e.g.,
results of two or more focus groups for content valid-
ity, strong correlations with two similar measures for
construct validity). Qualitative data require investiga-
tors to make a solid case about saturation of informa-
tion (i.e., documentation that further studies do not
generate new information).
Sample sizes for quantitative analyses should be
large enough to meet a desired level of measurement
precision or standard error [13]. With sample sizes of
100, 200, 300, and 400, the standard errors around a
correlation are approximately 0.05, 0.03, 0.03, and
0.02, respectively. A sample of 300 yields 84% power
(alpha = 0.05, two-tailed) to detect a correlation
between two variables of 0.17. For factor analyses, at
least ﬁve cases per variable and a minimum of 300
cases have been recommended [14] and Charter [15]
argued for a minimum of 400 subjects for reliability
and validity studies. Reeve and Fayers [16] suggested
sample sizes of at least 200 for the simple one-
parameter (e.g., Rasch) IRT model. At this sample size,
the modeled item standard errors (2/(square root [N])
< standard error < 3/(square root[N])) are in the range
of 0.14–0.21 [17]. For two-parameter (e.g., graded
response) models, a sample size of at least 500 was
recommended [16]. Hence, the sample size require-
ments for reliability and validity assessment depend on
the speciﬁc circumstances and analytical tools, but a
minimum of about 200 cases is suggested for even the
most basic psychometric analyses. If a measure is to be
used in a speciﬁc subgroup (e.g., African Americans),
then sufﬁcient sample size is needed to represent that
subgroup. In some situations (e.g., when large patient
accrual is not feasible) a smaller sample size might
be considered sufﬁcient. In this situation, analytical
methods can include simple descriptive statistics of
correlations among items and subscales.
Replication of psychometric estimates is needed
either by a sufﬁciently large and representative sample
that can be split into two subsamples for cross-
validation or two samples of sufﬁcient sample size.
One sample is used to explore the properties of the
scale and the second sample is used to conﬁrm ﬁndings
found with the ﬁrst sample. If the results of the two
samples are inconsistent, then psychometric estimates
from another sample may be required to establish the
properties of the measure. Clinical trial data can be
used to support the psychometric properties of an
instrument.
When evaluating the reliability and validity of an
existing instrument, a review of the literature typically
reveals the needed information. Nevertheless, a more
comprehensive evaluation may also involve sponsor
communication with the developer or other investiga-
tors to identify unpublished data. The goal of the
evaluation is to determine the level of evidence that is
available in circumstances (e.g., population, mode of
administration, intervention) similar to those of the
proposed clinical trial. The amount of existing docu-
mentation may depend on how long the instrument
has been available, the population(s) in which it has
been used, prevalence of the conditions measured, and
the speciﬁcity of the instrument to certain subgroups.
When the existing evidence is not sufﬁcient, additional
documentation must be produced.
Investigators should generate at least one full report
on the development and evaluation of the instrument.
In addition, they should have at least one report on the
use of the instrument in an interventional setting, such
as a clinical trial or naturalistic study, to conﬁrm fea-
sibility and psychometric attributes. These reports
should provide detailed information on patient popu-
lation, sample size, instrument administration, scoring
methods, statistical analyses, and evidence of stability
of ﬁndings.
When PROs are secondary end points in clinical
trials, the level of detail provided in the primary pub-
lication of the results of the trial rarely includes the
psychometric properties of the PRO instrument. Addi-
tionally, there may be no secondary publications that
focus on the PRO end point. Thus, to obtain the PRO
psychometric properties, follow-up with the developer
or investigators may be indicated. Availability of
reports may be limited if publications are still under
review or if the developer or investigator prefers to
restrict use of the PRO measure for proprietary
reasons.
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Contexts That May Affect
Psychometric Properties
Although information about the reliability and validity
of an instrument is critical, these properties must be
considered in the context of the setting in which the
instrument will be used. The context may change the
ability of the instrument to measure the desired con-
struct. The following section outlines some factors
that should be considered when evaluating available
reports.
Patient Population
Particular attention should be given to the compara-
bility of patient populations in reports relative to the
target population. Unique characteristics of the target
population that might result in variations in the results
of a PRO assessment should be identiﬁed in advance.
These might include age, gender, race and ethnicity,
martial status, socioeconomic status, education,
comorbidities, disease status whether the condition is
acute or chronic, and whether the intervention is cura-
tive or palliative.
A PRO item bank might be used to address a variety
of contextual concerns, such as population differences
and repeated measures, which may affect reliability
and validity. An item bank is a collection of items that:
1) measure a single domain; 2) have undergone rigor-
ous qualitative, cognitive and psychometric review
(including cross-cultural group validations); and 3)
have been IRT-calibrated with a set of properties
allowing instrument developers to select an item set
matched to the characteristics of the study population
[18].
Investigators can use the bank to reduce response
burden by developing short-form instruments that
select subset of items. Turner et al. (2007) in this
supplement review the value and potential of item
banks (article 3 of this series) [19]. The strength of a
bank to deliver reliable, valid, and efﬁcient measure-
ment depends, as with any other PRO instrument, on
the developmental process. Similar to the developmen-
tal process outlined in Fig. 1, an item bank should start
with a conceptual framework that leads to identifying
existing items that measure that domain and/or devel-
oping new items (see Rothman et al. in this supple-
ment) [20]. Once the item pool has been built of old
and new items, users must carry out a thorough quali-
tative review phase beginning with evaluating the
items. Next, response data with a large sample repre-
sentative of the target population must be collected
and used to review the item performance quantita-
tively and make IRT-calibrations. The quantitative
review phase requires assessing the psychometric
domains of reliability and validity described in this and
other articles [21–23]. Essentially, the attributes that
make up a quality item bank do not differ materially
from the attributes of any other PRO instrument under
consideration.
Cross-cultural application. Patient-reported outcomes
instrument development and initial application may be
from a single institution; this factor frequently limits
the generalization to other settings and patient popu-
lations, including cultural backgrounds. Ideally, addi-
tional PRO measure reports will have been applied
across multiple study sites and potentially across mul-
tiple countries to address cross-cultural issues. Docu-
mentation that appropriate cross-cultural validation
methods were used in the development of translations
should also be available [24].
Recall
A critical issue is the instrument’s recall (or reference)
period. The recall period should be considered relative
to the disease condition and the intervention. Symp-
toms that change every day, such as level of pain or
fatigue, pose difﬁculties when individuals are asked to
recall this information. Nevertheless, with other areas
in which changes may not take place every day or even
every week, recall over the last month may be more
informative. Examination of the bias associated with
recall can be addressed by ecologic momentary assess-
ment [25]. With this approach, investigators survey
individuals in environments that represent their real
world, they collect data at the moment the situation of
interest is occurring, and they take multiple samplings.
In general, recall over a few days to a few weeks is less
problematic than recall over a longer period of time.
Variations in Instrument Administration
Mode of administration. The method of data collec-
tion (e.g., in-person interview, article, telephone,
electronic, Internet, proxy) can produce different
systematic results, raising questions about the inter-
changeability of the methods [26]. To evaluate mode
effects, a substudy can be conducted in which study
participants are randomized to different modes of
administration. Item missing data, means, SDs, item-
scale correlations, reliability, and correlations of items
and scales with other variables can be compared by
mode.
Timing of assessments. Frequency or timing of assess-
ments may alter ﬁndings in situations where a patient’s
condition is unstable because of disease or an interven-
tion, if an intervention causes acute toxicity such as
with cyclic administration of cytotoxic chemotherapy,
or if surgical interventions have occurred.
Proxy measures. Investigators need to be cautious in
trying substitute proxy reports for patient self-report
data because of inherent differences between the two
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types of respondents. The more observable the func-
tion, the greater the agreement between a proxy and a
patient’s report; better concordance between proxies
and patients tends to occur for the physical domains
than for psychosocial domains [27,28]. Proxies tend
to report more disability and depression about the
patients than patients report about themselves. In con-
trast, proxies tend to attribute higher levels of cogni-
tive ability to the patients than do patients when rating
their own cognitive ability. For speciﬁc cognitive and
depression instruments such as the Mini Mental State
Examination and the Center for Epidemiologic Studies
depression scale, scoring on a continuous scale com-
pared to an impaired/unimpaired dichotomy showed a
higher level of concordance between patient and proxy
than did an impaired/unimpaired dichotomy. Never-
theless, an impaired/unimpaired dichotomy, compared
to a continuous scale, results in less of a biased esti-
mate of impairment [27].
Statistical Analysis
Investigators need to determine the reasons for the
presence or absence of statistically or clinically signiﬁ-
cant differences between groups. A lack of differences
may be a result of the PRO instrument lacking the
sensitivity needed (articles Sloan et al. [29] and Snyder
et al. [30] in this series cover these points in more
detail). Nevertheless, this may also be a result of
limited sample size (see sample size discussion in Level
of Psychometric Evidence to Support Use of PROs in
Clinical Trials section), missing data, or appropriate-
ness of analysis.
The apparent sensitivity of the PRO measure may
depend on how the data are reported. For example,
broad PRO claims such as overall health-related
quality of life and total symptom scores can obscure
the changes that are occurring within individual con-
cepts or symptoms. A summary score may obscure the
fact that the person is having great difﬁculty with
social function when the person is doing well on the
other aspects of health-related quality of life. The total
score does not reﬂect this speciﬁc difﬁculty. Thus,
looking at speciﬁc domains as a proﬁle along with the
summary score(s) is critical [31]. Additionally, report-
ing only group differences may obscure individual
patient changes that are signiﬁcant.
Stability of Findings
When considering a PRO instrument that does not
appear to produce consistent ﬁndings, investigators
need to determine whether this lack of consistency
occurred because of differences in methodology of the
reports including variations in number of investigative
sites, population characteristics, sample size, instru-
ment administration, analysis, and the intervention. If
any estimates fall outside of accepted values, this varia-
tion should be explained. This explanation is most
critical if this variation is reported in a setting similar
to the target indication or population. A compelling
case would need to be built as to why this particular
PRO measure would be used in light of inconsistent
reports.
Methods to Evaluate PRO InstrumentsWhen
the Format and Application of the PRO Is
Different from Previous Psychometric
Evaluation Studies
Determining the need for additional psychometric
evaluation of a PRO measure is tricky. Some suggest
(in the context of using an instrument in a new cultural
population) any small changes in the items, formula-
tion, or design can affect respondents’ understanding
of the items or accuracy of the measurement [32].
Ideally, an instrument would be reevaluated when any
changes or adaptations occur, but burden, time, and
budgetary constraints may make further psychometric
testing infeasible. The article by Snyder et al. [30] in
this supplement addresses these issues and makes rec-
ommendations under what conditions sponsors should
feel comfortable that the properties of the instrument
are robust to minor modiﬁcations. Nevertheless, if a
sponsor decides to reevaluate the instrument, then
several qualitative and quantitative approaches or
tools are available (Fig. 3); we discuss their strengths
and limits next. The same approaches or tools can be
used to initially create an instrument as presented by
Turner et al. in this series [19].
Qualitative Approaches
Focus groups. Focus groups typically consist of a
moderator interacting with 6 to 12 people representing
the target population, or signiﬁcant others (e.g., family,
health-care providers) involved with the target popu-
lation. Focus groups may be used during all stages of
instrument development and evaluation (see Fig. 3). In
early stages, focus groups may respond to open-ended
questions that elicit information about important
issues and concerns about the PRO construct. This
may uncover cultural differences in the experiences of
the PRO domain. Further, focus groups can produce
feedback on item formulation and how items are per-
ceived. For lengthy instruments, focus group members
typically complete the instrument in advance and the
moderator may ask individuals to discuss complex
terms and identify unclear items. Focus groups may
also help in generating hypotheses or explanations for
interpreting data that have been collected [33].
Behavioral coding. In behavioral coding, the interac-
tions between the interviewer and respondent in inter-
views are recorded, coded, and analyzed to identify
overt sources of error and to evaluate the adequacy of
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proposed questions. This process can be labor inten-
sive, especially if the researchers code all aspects
of the interview including response time. Alternate
approaches may rely on a limited set of codes that
represent key behaviors; examples include respondent
need for an item repeated or clariﬁed [33]. For assess-
ing conceptual equivalence across racial or cultural
groups, computer-assisted telephone interviews or
computer-assisted personal interviews are conducted
for each group. Errors associated with one group can
identify problems in the translation or cultural rel-
evance of the items. Behavioral coding provides aggre-
gate coding summaries of interviews conducted in
samples of 50 respondents or more [34,35] although
sample sizes signiﬁcantly vary across studies.
Cognitive interviewing. Cognitive interviewing is a
powerful tool for gaining a better understanding of the
underlying or covert process involved in responding to
survey items through the use of verbal probing tech-
niques [36]. It is used to evaluate the quality of each
item in terms of a person’s understanding of the
item, ability to retrieve the appropriate information,
decision-making on reporting retrieved information,
and selection of the response. Further, cognitive inter-
views can be used to examine relationships between
participant characteristics, such as ethnicity, and
responses to survey items.
The cognitive interview process includes both the
administration of an instrument and the collection
of additional verbal information about the survey
responses [36]. Cognitive interviewing encompasses the
more speciﬁc practice of cognitive debrieﬁng. The term
“cognitive debrieﬁng” is typically associated with
following-up with a respondent through the use of
retrospective probes after they have completed an
instrument with a line of questions aimed at uncovering
any difﬁculties the person may have experienced with
either the item content or instructions. For cognitive
interviews that involve concurrent probing, the inter-
viewer follows each question with a series of probes to
capture patient understanding. In contrast to the retro-
spective cognitive debrieﬁng, concurrent probing can
yield information about the cognitive processing of the
item at a point close in time to when it is ﬁrst presented.
Using 5–12 persons is recommended for cognitive inter-
views, with a second, iterative round of testing to
evaluate items revised from the ﬁrst round [35].
Cognitive interviews can include two types of
probes. Scripted probes ensure that particular informa-
tion is collected in every interview so that it can be
compared across all interviews. Emergent, nonscripted
probes to help interviewers make sense of gaps or
contradictions in participants’ responses and provide
contextual information needed to deﬁne item problems
precisely. If sufﬁcient numbers of cognitive interviews
are conducted, a coding mechanism allows researchers
to utilize quantitative methods (e.g., logistic regres-
sion) to determine if problems encountered during the
interviews can be attributed to speciﬁc factors, such as
cultural effects. Cognitive interviewing has been
employed as an instrument evaluation tool in several
PRO studies [32,36,37].
Quantitative Approaches
Differential item functioning. Several quantitative
approaches are available for evaluating measurement
invariance in the form of differential item functioning
(DIF) testing. DIF tests whether one group responds
differently to an item than another group despite con-
trolling for differences between the two groups on the
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Figure 3 Qualitative and quantitative methods
available for strengthening the validation
process during PRO instrument development
and evaluation. PRO, patient-reported outcome.
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measured construct. Between-group comparisons for
instruments containing such items are problematic,
because scores from the two groups may be indicative
of a variety of factors other than those the instrument
is intended to measure.
Methods for DIF testing include IRT modeling
[37–39], structural equation modeling [40], and
regression models [41]. DIF methods typically examine
whether the associations between the estimated under-
lying attribute and items in the instrument vary by
subgroup. DIF testing is performed on an item-by-item
basis controlling for group differences using the other
items within the instrument or covariates. Any empiric
ﬁnding that DIF is present should be followed by the
other qualitative techniques to understand the under-
lying causes.
Each qualitative and quantitative method above
has its strengths and weaknesses in terms of gained
information, resource constraints, and burden on the
administrators and respondents [35]. Each can be
applied at different stages of instrument development
and evaluation. Incorporating more than one method-
ology enhances the strength of the validation process
(see Fig. 3). When problematic items have been iden-
tiﬁed and the source of the problem understood, items
might be rewritten, removed from the instrument, or
statistically controlled for when computing individual
scores.
Additional Sources to Enhance Validity and Complement
the PRO
Sources for validating PRO instruments or increasing
the information gained from PROs can be found in
other clinical-based or performance-based measures.
For instance, a surgical patient’s hemoglobin level pro-
vides information relevant to the patient’s subjective
report of fatigue. A combination of self-report and
performance-based measures may maximize the infor-
mation value as evidenced by prediction of hospital
costs [42] and mortality [43].
PRO Use in Clinical Trials as a Means to Gain
Additional Psychometric Information
Testing the PRO instrument in early clinical develop-
ment phases of an intervention is valuable in terms of
establishing its attributes in a setting most similar to
the anticipated registration trial. The opportunity to
include PRO measures within early phase trials may
depend on whether the PRO is considered a primary or
secondary end point. Phase I trials may not be optimal
because study participants often do not suffer from the
target condition, although exceptions exist, as in the
case of cancer.
Phase II trials offer a better opportunity to assess
how the instrument performs relative to a consistent
dose and within a speciﬁc patient population.
Psychometric properties can be reevaluated and
analysis methods explored to generate hypotheses for
Phase III. The Phase III population may differ from
the Phase II population. If broader, one must rely on
the evidence from other reports to assess how this will
affect the PRO assessment. If narrower, PRO data
from a subgroup of the Phase II population may be
reevaluated. Nevertheless, sample sizes in Phase II
trials may range from 40 to 200 patients, and this
small number may limit subgroup evaluations. If mul-
tiple Phase III trials are conducted, they can provide
additional information about the psychometric prop-
erties of a PRO instrument.
Evaluation of Psychometric Properties in Phase II Trials
Phase II trials appear to be the most obvious choice for
exploring the concept of interest and the associated
validation issues. Phase II trials may allow for the
evaluation of the PRO relative to other clinical mea-
sures. These can contribute to estimating the mini-
mally important difference for the PRO instrument in
a speciﬁc target population and interventional setting.
In short, Phase II may provide the opportunity for
hypothesis generation and for considering sample sizes
for Phase III trial design.
Evaluation of Psychometric Properties in Parallel with
Phase III
When PROs are secondary end points in clinical trials,
the progression of clinical development does not
always allow for full evaluation of an instrument
before starting Phase III research. In such a situation,
the sponsor may be willing to assume the risk of con-
ducting evaluation studies in parallel with Phase III or
within the Phase III trial itself. This type of situation
may arise when the need for a modiﬁcation is identiﬁed
in Phase II, but evaluation studies can not be com-
pleted before initiating Phase III. Although not ideal,
this situation is common in drug development.
Evaluation of PRO Properties in Phase IV Studies
Phase IV studies that further explore the PRO may be
useful in further establishing PRO reliability and valid-
ity. Demonstrating adequate psychometric perfor-
mance for any PRO supports the data as meaningful in
the real world. Clinical trials are criticized as being
artiﬁcial and not based on patient-experienced reality,
because trials are conducted under strict conditions
(tight enrollment standards, randomized, placebo-
controlled, double-blinded) to minimize bias and mini-
mize patient variability. These heavily orchestrated
operations are costly and time consuming; yet they
remain the standard by which regulatory decisions are
made. PRO instruments that can withstand the rigors
of such an operation gain credibility over time as tools
in the decision-making process.
S102 Frost et al.
Eventually these tools can ﬁnd their way into the
more common clinical vernacular of Phase IV postmar-
keting trials. The therapeutic intervention is subject to
wider ranges of bias and variability to reﬂect what
happens in the real world. In these settings, effective-
ness (deﬁned as the balance of risk vs. therapeutic
beneﬁt) may be more important than efﬁcacy (deﬁned
as the ability of the drug to show statistical superiority
or noninferiority to a comparator). Therefore, a PRO
might take on more of a lead role as the primary
outcome domain.
An example of the use of a Phase IV study is found
in the sleep literature [44]. In the context of excessive
daytime sleepiness (EDS) in normal subjects versus
EDS in narcoleptics, the investigator provided
sensitivity- and speciﬁcity-based evidence that sup-
ported the abandonment of the historical “gold stan-
dards,” the Multiple Sleep Latency Test (MSLT) and
the Maintenance of Wakefulness Test (MWT), in favor
of the Epworth Sleepiness Scale (ESS; a simple eight-
item, self-administered questionnaire). The investiga-
tor demonstrated that the MSLT and MWT were not
as valid as the ESS because the latter better discrimi-
nated the EDS of narcolepsy from the EDS of normal
subjects.
Summary
Table 1 summarizes the considerations for evaluating
reliability and validity of PROs. Demonstrating reli-
ability and validity is essential for determining whether
a speciﬁc PROmeasurement will be useful in the evalu-
ation of a health-care intervention. These psychomet-
ric properties are on a continuum in which more
evidence provides greater conﬁdence in the value of the
PRO data. The level of support for psychometric prop-
erties of a concept should be more extensive when the
application presents greater stakes or potential conse-
quences to individuals.
Proof of reliability is essential to ascertain that one
is consistently measuring the same concept or dimen-
sions of a single concept. For clinical trials, the 0.70
minimum reliability threshold is appropriate. To trans-
late ﬁndings to the individual, higher reliabilities are
preferred. Carrying equal importance is validity, which
is ascertaining that the concept of interest is the one
being measured. Construct validity will generally be an
acceptable approach with PRO instruments. Content
validity is important but only provides beginning evi-
dence of validity. Criterion validity is difﬁcult as rarely
is there a PRO “gold standard” that can be used.
Several guidelines are recommended for establish-
ing sufﬁcient evidence for reliability and validity. To
provide initial estimates of reliability and validity,
samples sizes should be at least 200 cases and reliabil-
ity and validity should be replicated in at least one
additional representative sample. Subsamples may be
created for cross-validation. Existing instruments,
including item banks, should have at least one full
report on their development and evaluation and one
report on their use in an interventional setting. If the
population characteristics or manner in which the
PRO is administered vary from how the investigator
intends to use the PRO, then additional psychometric
information will be needed. To gain additional validity
data, qualitative approaches such as focus groups,
behavioral coding, and cognitive interviewing or the
quantitative approach of DIF testing may be useful. If
reliability and validity have not been adequately evalu-
ated before Phase III testing begins, the sponsor
assumes considerable risk in not being able to substan-
tiate the use of the PRO. Phase II trials are an appro-
priate venue for evaluating psychometric properties
for a target population and minimally important
differences.
Source of ﬁnancial support: Ron D. Hays was supported in
part by the UCLA/DREW Project EXPORT, National Insti-
tutes of Health, National Center on Minority Health &
Health Disparities (P20-MD00148-01), the UCLA Center for
Health Improvement in Minority Elders/Resource Centers
for Minority Aging Research, National Institutes of Health,
National Institute of Aging (AG-02–004), and the National
Institute of Aging (P01-AG-02–079). Funding for the Mayo/
FDA meeting was provided by the Mayo Foundation in the
form of unrestricted educational grants; North Central
Cancer Treatment Group (NCCTG) (CA25224-27) and
Mayo Comprehensive Cancer Center grants (CA15083-32).
References
1 ERIQA Group. Comments on the Reﬂection paper
on the regulatory. Guidance for the Use of Health-
Table 1 Reliability and validity of PROs: summary points
• Usefulness of a PRO measure depends on reliability and validity
• Reliability and validity lie on a continuum such that more evidence
produces more conﬁdence in PRO data
• Reliability indicates that the same concept or dimensions of a single
concept is consistently measured
• Minimum reliability threshold for clinical trials is 0.70
• Higher reliability of a PRO instrument will decrease sample size
needed to detect a change in the PRO
• Validity indicates that the concept of interest is being measured
• Construct validity is a generally acceptable approach with PROs
• Ideally, sample sizes of at least 200 should be used to provide initial
estimates of reliability and validity
• To gain additional validity data several qualitative and quantitative
approaches are available
• Qualitative—focus groups, behavioral coding, cognitive interviewing
• Quantitative—item response theory, differential item functioning
• PRO item banks are a valuable resource for building standardized and
linked short-form instruments or computer-adaptive tests.Their
psychometric properties should be evaluated in ways similar to those
used to evaluate any other PRO instrument.
• Phase II trials are useful for identifying small, but important
differences
• Phase III need to be powered for PRO differences
• In Phase IV trials PROs often become more important than in earlier
phase trials
PRO, patient-reported outcome.
PROs Reliability and Validity S103
Related Quality of Life (HRQOL) Measures in the
Evaluation of Medicinal Products. Available from:
http://www.eriqa-project.com/ [Accessed March 15,
2007]
2 Morris LA, Miller DW. The regulation of patient-
reported outcome claims: need for a ﬂexible standard.
Value Health 2002;5:372–81.
3 Du Bois D. Meeting Report, Session 2: How to inte-
grate patient-reported outcomes in international
trials? Regulatory issues. Acquadro C, ed. Patient
Related Outcomes Newsletter. Lyon: MAPI Research
Trust, 2005;3:6–10.
4 Scientiﬁc Advisory Committee of the Medical Out-
comes Trust. Assessing health status and quality-of-
life instruments: Attributes and review criteria. Qual
Life Res 2002;11:193–205.
5 U.S. Department of Health and Human Services.
[Draft]. Guidance for Industry: Patient-Reported
Outcome Measures: Use in Medical Product Deve-
lopment to Support Labeling Claims. Available
from: http://www.fda.gov/cder/guidance/5460dft.pdf
[Accessed March 15, 2007].
6 Nunnally J. Psychometric Theory (2nd ed.). New
York: McGraw-Hill, 1978.
7 Fries JF, Bjorner JB, Lingala B, Sun X. Improving
measurement precision can reduce sample size
requirement for clinical trials. Ann Rheum Dis
2006;65(Suppl. 3):III16-21.
8 Zimmerman DW, Williams RH. Note on the reliabil-
ity of experimental measures and the power of signiﬁ-
cance tests. Psych Bull 1986;100:123–4.
9 Jackson DN. A sequential system for personality scale
development. In: Spielberger CD, ed., Current Topics
in Clinical and Community Psychology. New York:
Academic Press, 1970.
10 Hays RD, Fayers P. Evaluating multi-item scales. In:
Fayers P, Hays R, eds. Assessing Quality of Life in
Clinical Trials: Methods and Practice (2nd ed.).
Oxford: Oxford University Press, 2005, 41–53.
11 McDowell I. Measuring Health (3rd ed.). New York:
Oxford University Press, 2006.
12 Hays RD, Hadorn D. Responsiveness to change. an
aspect of validity, not a separate dimension. Qual Life
Res 1992;1:73–5.
13 Thissen D, Wainer H. Some standard errors in item
response theory. Psychometrika 1982;47:397–412.
14 Tabachnick BG, Fidell LS. Using Multivariate Statis-
tics (3rd edn). New York: Harper Collins, 1996.
15 Charter RA. Sample size requirements for precise
estimates of reliability, generalizability, and validity
coefﬁcients. J Clin Exp Neuropsychol 1999;21:559–
66.
16 Reeve BB, Fayers P. Applying item response theory
modeling for evaluating questionnaire items and scale
properties. In: Fayers P, Hays R, eds., Assessing
Quality of Life in Clinical Trials: Methods and
Practice (2nd ed.). Oxford: Oxford University Press,
2005.
17 Wright BD, Stone MH. Best Test Design. Chicago, IL:
MESA Press, 1979.
18 Reeve BB. Special issues for building computerized-
adaptive tests for measuring patient-reported out-
comes. The National Institute of Health’s investment
in new technology. Med Care 2006;44(11 Suppl.
3):S198–204.
19 Turner RR, Quittner AL, Parasuraman BM, et al.
Patient-reported outcomes: instrument develop-
ment and selection issues. Value Health 2007;
10(Suppl. 2):S86–93.
20 Rothman ML, Beltran P, Cappelleri JC, et al. Patient-
reported outcomes: conceptual issues. Value Health
2007;10(Suppl. 2):S66–75.
21 Ware JE Jr, Bjorner JB, Kosinski M. Practical impli-
cations of item response theory and computerized
adaptive testing: a brief summary of ongoing studies
of widely used headache impact scales. Medical Care
2000;38:II73–82.
22 Bjorner JB, Kosinski M, Ware JE Jr. Calibration of an
item pool for assessing the burden of headaches: an
application of item response theory to the headache
impact test (HIT). Qual Life Res 2003;12:913–33.
23 Lai JS, Cella D, Chang CH, et al. Item banking to
improve, shorten and computerize self-reported
fatigue: an illustration of steps to create a core item
bank from the FACIT-Fatigue Scale. Qual Life Res
2003;12:485–501.
24 Acquadro C, Conway K, Giroudet C, Mear I. Linguis-
tic Validation Manual for Patient-Reported Outcomes
(PRO) Instruments. Lyon: MAPI Research Institute,
2004.
25 Gendreau M, Hufford MR, Stone AA. Measuring
clinical pain in chronic widespread pain: selected
methodological issues. Best Pract Res Clin Rheumatol
2003;17:575–92.
26 Hepner KA, Brown JA, Hays RD. Comparison of mail
and telephone in assessing patient experiences in
receiving care from medical group practices. Eval
Health Prof 2005;28:377–89.
27 Magaziner J, Zimmerman SI, Gruber-Baldini AL,
et al. Proxy reporting in ﬁve areas of functional status:
comparison with self-reports and observations of per-
formance. Am J Epidem 1997;146:418–28.
28 Frost MH, Bonomi AE, Ferrans CE, et al. Patient,
clinician, and population perspectives on determining
the clinical signiﬁcance of health-related quality of life
scores. Mayo Clin Proc 2002;77:488–94.
29 Sloan JA, Dueck A, Erickson PA, et al. Analysis and
interpretation of results based on patient-reported
outcomes. Value Health 2007;10(Suppl. 2):S106–
15.
30 Snyder CF, Watson ME, Jackson JD, et al. Patient-
reported outcome instrument selection: designing a
measurement strategy. Value Health 2007;10(Suppl.
2):S76–85.
31 Sloan JA, Aaronson N, Cappelleri JC, et al. Assessing
the clinical signiﬁcance of single items relative to sum-
mated scores. Mayo Clin Proc 2002;77:488–94.
32 Harkness J, Pennell B-E, Schoua-Glusberg A. Survey
questionnaire translation and assessment. In: Presser
S, Rothgeb JM, Couper MP, et al., eds. Methods for
Testing Evaluating Survey Questionnaires. Hoboken,
NJ: Wiley, 2004.
33 Aday LA. Designing and Conducting Health Surveys
(2nd ed.). San Francisco: Jossey-Bass, 1996.
S104 Frost et al.
34 Zukerberg AL, Von Thurn DR, Moore JC. Practical
considerations in sample size selection for behavior
coding pretests. Proceedings of the Section on Survey
Research Methods. Amer Stat Assoc, 1995.
35 Willis G. Beyond cognitive testing. In: Willis GB, ed.,
Cognitive Interviewing: A Tool for Improving Ques-
tionnaire Design. Thousand Oaks, CA: Sage, 2005.
36 Harris-Kojetin LD, Fowler FJ, Brown JA, et al. The
use of cognitive testing to develop and evaluate
CAHPS™ 1.0 core survey items. Med Care 1999;
37(Suppl.):MS10–21.
37 Morales LS. Assessing patient experiences with assess-
ing healthcare in multi-cultural settings. RAND, Santa
Monica, CA. Dissertation (chapter 2) 2000. Available
from: http://www.rand.org/pubs/rgs_dissertations/
RGSD157/ [Accessed March 15, 2007].
38 Thissen D, Steinberg L, Wainer H. Detection of dif-
ferential item functioning using the parameters of item
response models. In: Holland PW, Wainer H, eds.
Differential Item Functioning. Hillsdale, NJ:
Lawrence Erlbaum Associates, 1993.
39 Raju NS, van der Linden WJ, Fleer PF. IRT-based
internal measures of differential functioning of items
and tests. Appl Psychol Measurement 1995;19:353–
68.
40 Fleishman JA, Lawrence WF. Demographic variation
in SF-12 scores: true differences or differential item
functioning. Medical Care 2003;41:III75–86.
41 Zumbo BD. A Handbook on the Theory andMethods
of Differential Item Functioning (DIF): Logistic
Regression Modeling as a Unitary Framework for
Binary and Likert-type (Ordinal) Item Scores. Ottawa,
ON: Directorate of Human Resources Research
and Evaluation. Department of National Defense,
1999.
42 Reuben DB, Seeman TE, Keeler E, et al. The effect
of self-reported and performance-based functional
impairment on future hospital costs of community-
dwelling older persons. Gerontologist 2004;44:
401–7.
43 Reuben DB, Seeman TE, Keeler E, et al. Reﬁning the
categorization of physical functional status: the added
value of combining self-reported and performance-
based measures. J Gerontology: Med Sci 2004;
59A:1056–61.
44 Johns MW. Sensitivity and speciﬁcity of the multiple
sleep latency test (MLST), the maintenance of wake-
fulness test and the Epworth sleepiness scale; Failure
of the MSLT as a gold standard. J Sleep Res 2000;9:5–
11.
PROs Reliability and Validity S105
